From patients to discoveries

CRYOSTEM, a national cohort dedicated to the complications of Hematopoietic Stem Cell Transplantation (HSCT)

More

Biological resources

The patient-biobank duo: the two pillars of novel precision medicine

More

CRYOSTEM biospecimen collection

Throughout the year, CRYOSTEM encourages researchers to apply for samples access

More

Research

CRYOSTEM supports fundamental, translational and clinical research projects in the field of HSCT complications

More

Partnerships

CRYOSTEM develops tailor-made biobanking network solutions for innovative projects and medical research

More
About CRYOSTEM

A collection unique in Europe

Launched within the framework of Investments for the Future by the National Research Agency (ANR), at the heart of the French Government’s Plan Cancer and supported by the National Cancer Institute (INCa), the CRYOSTEM’s project was initiated in 2011 under the auspices of the Francophone Society of Marrow Transplantations and Cellular Therapy (SFGM-TC) to accelerate research in the area of complications of Hematopoietic Stem Cell Transplantation (HSCT), previously called bone marrow transplantation. Today, CRYOSTEM brings together all French transplant units, 28 Biological Resource Centers (BRC) as well as more than 400 French research and healthcare players in the field of severe blood diseases.

More

CRYOSTEM network partnering centers
(transplant units and biological resource centers)

Today the CRYOSTEM community offers academic and industrial research teams, a collection of almost 200 000 samples to address life-threatening complications of HSCT.

Dr. Boris Calmels
Department of Hematology and Cell Therapy
Institut Paoli-Calmettes,
Founding Member of CRYOSTEM

 

CRYOSTEM is a wonderful opportunity for researchers to better understand the biological mechanisms, to improve the prevention and the management of the complications of HSCT.

Prof. Jean-Hugues Dalle
Department of Pediatric Hematology,
Robert Debré Hospital (AP-HP)

Throughout the year, CRYOSTEM encourages researchers to apply to gain access to the collection.

Dr. Emilie Robert
CRYOSTEM strategy and development manager

What interests us it is being able to discriminate early before transplantation between patients who are going to benefit from the treatment.

Pr. Régis Peffault de Latour
Department of Hematology,
The Saint Louis Hospital (AP-HP),
Founding Member of CRYOSTEM

82%

of transplanted patients in France

  • 5 985 Recipients
  • 2 437 Donors
  • 17 983 Blood samples
  • 46 486 Samples (182 103 aliquots)
  • 13 153 Provided aliquots

Publications

VALLET N. ET AL., 2022

Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation. Blood

LUPO J. ET AL., 2022

High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD. Pathogens

DUBOUCHET L. ET AL., 2022

Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. Science Translational Medicine.

TOURRET M. ET AL., 2021 

Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy. Journal for ImmunoTherapy of Cancer.

PIPEROGLOU C, LARID G, VALLENTIN B, ET AL., 2021

Innate lymphoid cell recovery and occurrence of GvHD after hematopoietic stem cell transplantation. J Leukoc Biol. 

LATIS E. ET AL., 2020

Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Advances. 

ROBERT E. ET AL, 2020

“CRYOSTEM Biobank: A National Prospective, Standardized Collection to Better Characterize Allogeneic Hematopoietic Stem Cell Transplantation Complications”. Open Journal of Bioresources. 

MICHONNEAU D. ET AL., 2019

Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nature Communications. 

DE MASSON A. ET AL., 2015

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 

 

Read a selection of publications
HTC PROJECT

CRYOSTEM is listed as a biobanking expert at Labtoo

Visit Labtoo

CRYOSTEM, a new model of biobanking networks

Contact Us